Allogene Therapeutics, Inc. (ALLO) Tops Q4 EPS by 6c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q4 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Vail Resorts (MTN) 2200 contracts October 145 puts trade into quarter results
• Accenture (ACN) call put ratio 1 call to 1.2 puts into quarter results
• FactSet (FDS) call put ratio 2.6 calls to put into quarter results